Last reviewed · How we verify
Mepivicaine
Mepivicaine is a Small molecule drug developed by University Health Network, Toronto. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Mepivicaine |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IV Steroids Versus Steroids Included in Block for Orthopedic Lower Limb Surgery (EARLY_PHASE1)
- Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty (PHASE4)
- Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy (NA)
- Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade (NA)
- Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks (PHASE4)
- Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepivicaine CI brief — competitive landscape report
- Mepivicaine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about Mepivicaine
What is Mepivicaine?
Who makes Mepivicaine?
What development phase is Mepivicaine in?
Related
- Manufacturer: University Health Network, Toronto — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing